Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Bild på Shai Mulinari. Privat bild.

Shai Mulinari

Docent | Universitetslektor

Bild på Shai Mulinari. Privat bild.

Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark

Författare

  • Shai Mulinari
  • Dylan Pashley
  • Piotr Ozieranski

Summary, in English

Pharmaceutical industry funding of patient organizations raises ethical challenges related to patient engagement in healthcare due to fears of commercial agendas influencing patient advocacy and creating industry-driven inequalities across patient organizations. We contribute to an international body of knowledge on patient organization–industry relations by analyzing all payments reported by companies in Denmark over a six-year period, 2014–2019. We performed descriptive analyses calculating the number, value, and distribution of payments for various units of analysis: all companies and patient organizations; individual companies and patient organizations; and the broader disease area (e.g., cancer) and narrower disease (e.g., breast cancer). Fifty-one companies reported paying €8,826,916 to 84 patient organizations. As in previously studied countries, the funding was dominated by a relatively small number of funders and recipients, and commercially high-profile diseases attracted most of the funding. Nevertheless, our study also highlighted the arguably concerning dominance of one company in Denmark, both at the level of overall funding and in funding specific patient organizations, during a time of great policy contention surrounding one of its drugs, the world’s top-selling medicine; i.e., switching patients to cheaper biosimilars to save big money for the healthcare system. Patient organizations have reasons to rethink some collaborations with companies, especially during policy contentions, and governments should ensure equitable funding to counteract risks posed by the concentration of industry funding.

Avdelning/ar

  • Sociologi
  • Sociologiska institutionen

Publiceringsår

2022-11-08

Språk

Engelska

Sidor

1256-1262

Publikation/Tidskrift/Serie

Health Policy

Volym

126

Issue

12

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Sociology
  • Health Care Service and Management, Health Policy and Services and Health Economy

Status

Published

Projekt

  • Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations

ISBN/ISSN/Övrigt

  • ISSN: 1872-6054